ライフサイエンスコーパス: CoQ10

1 the synthesis of ubiquinone or coenzyme Q10 (CoQ10).

2 used for the determination of coenzyme Q10 (CoQ10).

3 SA-ST) was used to encapsulate coenzyme Q10 (CoQ10).

4 atin treatment reduces circulating levels of CoQ10.

5 s of O-2 generation than those obtained with CoQ10.

6 tion between SMPs reconstituted with CoQ9 or CoQ10.

7 and pork breakfast sausages, fortified with CoQ10.

8 plements, and substantial recent exposure to CoQ10.

9 in CoQ10 biosynthesis may be treatable with CoQ10.

10 e found to be more stable in the presence of CoQ10.

11 f age, which was significantly attenuated by CoQ10.

12 caspase-2 activation, which is regulated by CoQ10.

13 emulsions was compared to emulsions without CoQ10.

14 tandard feed pellets with or without dietary CoQ10 (1 mg/kg body weight per day) supplementation.

15 er standard diet or a diet supplemented with CoQ10 (200 mg/kg/day) for five weeks.

16 Liquid CoQ10 250 mg followed by 150 mg TID for 5 days or placeb

17 n decreased migration, which was reversed by CoQ10 addition.

18 olled clinical trials of monopreparations of CoQ10 administered orally to cancer patients were includ

19 ated whether combining mild hypothermia with CoQ10 after out-of-hospital cardiac arrest provides addi

20 placebo, 1200 mg/d of CoQ10, or 2400 mg/d of CoQ10; all participants received 1200 IU/d of vitamin E.

21 Coenzyme Q10 (CoQ10), an antioxidant and mitochondrial cofactor, has s

22 Coenzyme Q10 (CoQ10), an antioxidant that supports mitochondrial funct

23 ong-term (6 mo) treatment with coenzyme Q10 (CoQ10), an endogenous antioxidant.

24 systemic administration of the water-soluble CoQ10 analog reduced oxidative-induced cochlear damage,

25 the putative functional relationship between Coq10 and Coq11 in yeast.

26 ntly (62%) greater in the group treated with CoQ10 and MPTP than in the group treated with MPTP alone

27 antly higher (37%) in the group treated with CoQ10 and MPTP than in the group treated with MPTP alone

28 and biochemical reconstitution of FSP1 with CoQ10 and NADH suppresses triacylglycerol peroxidation i

29 affected subjects showed reduced amounts of CoQ10 and often displayed a decrease in CoQ10-dependent

30 tive saposin B (sapB) has been shown to bind CoQ10 and subsequently be excreted.

31 sted by incorporating either reduced CoQ9 or CoQ10 and the lipophylic azoinitiator 2,2'-azobis(2,4-di

32 mg/d of CoQ10, and 86 received 2400 mg/d of CoQ10), and 65 participants (29 who received placebo, 19

33 ceived placebo, 19 who received 1200 mg/d of CoQ10, and 17 who received 2400 mg/d of CoQ10) withdrew

34 4 received placebo, 87 received 1200 mg/d of CoQ10, and 86 received 2400 mg/d of CoQ10), and 65 parti

35 roblasts from patients had reduced levels of CoQ10, and abnormal accumulation of the biosynthetic pre

36 he calibration graph was 0.03-0.50mumolL(-1) CoQ10, and the detection limit was 0.008mumolL(-1).

37 nes or coenzyme Q (CoQ) homologues, CoQ9 and CoQ10, are related with the rate of O-2 generation was t

38 CoQ10 at 2,700 mg daily for 9 months shows insufficient

39 es showed no significant differences between CoQ10 at 2,700 mg/day and placebo.

40 chromatography) resin and successfully bound CoQ10 at pH 5.0 with release of the CoQ10 at pH 9.0.

41 ly bound CoQ10 at pH 5.0 with release of the CoQ10 at pH 9.0.

42 dings indicate a molecular pathway involving CoQ10 biosynthesis deficiency and mitochondrial dysfunct

43 in ADCK4 or other genes that participate in CoQ10 biosynthesis may be treatable with CoQ10.

44 ocytes, ADCK4 interacted with members of the CoQ10 biosynthesis pathway, including COQ6, which has be

45 The connection of HPDL to CoQ10 biosynthesis provides crucial insights into the me

46 fic respiratory chain complexes (I, III, and CoQ10 biosynthesis) increased ROS, whereas knockdown of

47 ects in three of the nine genes required for CoQ10 biosynthesis, all of which are associated with ear

48 several genes encoding proteins involved in CoQ10 biosynthesis.

49 We focused on the coenzyme Q10 (CoQ10) biosynthesis gene Coq2, the silencing of which di

50 le for the penultimate step of coenzyme Q10 (CoQ10) biosynthesis in mitochondria.

51 oding an enzyme essential for co-enzyme Q10 (CoQ10) biosynthesis, has been associated with MSA.

52 s been shown to participate in coenzyme Q10 (CoQ10) biosynthesis.

53 eteromeric complex that contains most of the CoQ10 biosynthetic enzymes.

54 entation can raise the circulating levels of CoQ10, but data on the effect of CoQ10 supplementation o

55 The extracts were analyzed for CoQ10 by high-performance liquid chromatography (HPLC).

56 Quantification of CoQ10 by HPLC showed that the retention of this lipophil

57 deletion of MDM12, we show that deletion of COQ10 by replacement with a HIS3 marker results in dimin

58 Our results indicate that CoQ10 can attenuate the MPTP-induced loss of striatal do

59 Consequently, CoQ10 can be tested in patients requiring statin treatme

60 tigations are necessary to determine whether CoQ10 can improve the tolerability of cancer treatments.

61 strated that by blocking caspase-2 activity, CoQ10 can protect the cells from mitochondrial membrane

62 The routine use of CoQ10 cannot be recommended in statin-treated patients.

63 heart SMPs with different amounts of CoQ9 or CoQ10 caused an initial increase in the rates of O-2 gen

64 subsequent introduction of Triton X-100 and CoQ10 causes the MLs lysis and the cresyl violet oxidati

65 The retention rate of CoQ10, composition and cheese yield were also determined

66 supplementation increased (P < 0.01) hepatic CoQ10 concentrations and ameliorated liver fibrosis (P <

67 Furthermore, cochlear levels of CoQ9 and CoQ10 content increased.

68 y CoQ9 and cow heart SMPs, with high natural CoQ10 content, were chosen for depletion/reconstitution

69 ought that this interaction between sapB and CoQ10 could be a mechanism to avoid any possible CoQ10 t

70 in a cheese matrix, hence demonstrating that CoQ10 could be used in the development of functional che

71 whether oral administration of coenzyme Q10 (CoQ10) could attenuate 1-methyl-4-phenyl-1,2,3,6-tetrahy

72 0 supplements in diseases other than primary CoQ10 deficiencies is insufficient.

73 s is recognized in the rare cases of primary CoQ10 deficiencies, a potential role for CoQ10 supplemen

74 Primary coenzyme Q10 (CoQ10) deficiencies are rare, clinically heterogeneous d

75 Significant CoQ10 deficiency and reduced MRC enzyme activities in th

76 CoQ10 deficiency has been identified in fibroblasts and

77 ient evidence to prove the etiologic role of CoQ10 deficiency in statin-associated myopathy and that

78 Awareness of CoQ10 deficiency is important because individuals with p

79 prompted the hypothesis that statin-induced CoQ10 deficiency is involved in the pathogenesis of stat

80 have been previously associated with primary CoQ10 deficiency, a clinically heterogeneous multisystem

81 s clinical presentations and associated with CoQ10 deficiency.

82 CK3) is one of several genes associated with CoQ10 deficiency.

83 performed sequencing of known Coenzyme Q10 (CoQ10) deficiency genes in 22 patients with unexplained

84 Ubiquinone (CoQ10) deficiency is one of the potentially treatable ca

85 in 1989, our understanding of coenzyme Q10 (CoQ10) deficiency is only now coming of age with the rec

86 lfide oxidation is impaired in Coenzyme Q10 (CoQ10) deficiency.

87 ess, and unable to synthesize Q(6) The yeast coq10 deletion mutant is also respiratory-deficient and

88 ome or all of the phenotypes associated with COQ10 deletion result from ERMES dysfunction.

89 s of CoQ10 and often displayed a decrease in CoQ10-dependent ETC complex activities.

90 lection, 35 participants per group) compared CoQ10 doses of 1,800 and 2,700 mg/day.

91 There are no known negative side effects of CoQ10 even at very high levels.

92 CoQ9 and inversely related to the amount of CoQ10, extractable from their cardiac mitochondria.

93 ims were to choose between two high doses of CoQ10 for ALS, and to determine if it merits testing in

94 The use of CoQ10 fortification in the production of a functional fo

95 hypothesize that the therapeutic effects of CoQ10, frequently administered to patients with primary

96 urs after CPR was significantly lower in the CoQ10 group (0.47 versus 3.5 ng/mL).

97 Three-month survival in the CoQ10 group was 68% (17 of 25) and 29% (7 of 24) in the

98 For the first time, CoQ10 has been encapsulated in a cheese matrix, hence de

99 The use of coenzyme Q10 (CoQ10) has been increasing rapidly during recent years d

100 Coenzyme Q10 (CoQ10) has shown a protective effect in neurodegenerativ

101 ved in the biosynthesis of the coenzyme Q10 (CoQ10) headgroup in human cells.

102 demonstrate that recombinant sapB will bind CoQ10 in a pH-dependent manner similar to sapB binding w

103 This fact, plus the role of CoQ10 in mitochondrial energy production, has prompted t

104 Overall, this study clarifies the role of Coq10 in modulating CoQ biosynthesis.

105 us trials during the past 30 years examining CoQ10 in patients with HF have been limited by small num

106 aimed to determine the bio-accessibility of CoQ10 in processed meat products, beef patties and pork

107 (-1) and was applied to the determination of CoQ10 in several food samples.

108 The average concentrations of CoQ10 in the choroid was 27+/-16 nanomoles/g dry choroid

109 The cooking retention level of CoQ10 in the products was found to be 74+/-1.42% for pat

110 The average concentration of CoQ10 in the retina was 42+/-11 nanomoles/g dry retina f

111 sone (DX), melatonin (MEL) and coenzyme Q10 (CoQ10)) in a single formulation (DMQ-MSs) to create a no

112 s, we show that supraphysiological levels of CoQ10 induces an increase in the expression of SQOR in s

113 CoQ10 is a highly lipophilic molecule with a chemical st

114 CoQ10 is an electron carrier in the mitochondrial electr

115 CoQ10 is an essential component of the electron transpor

116 In several fungi, Coq10 is encoded as a fusion polypeptide with Coq11, a r

117 CoQ10 is essential for multiple cellular functions, incl

118 of statin therapy on intramuscular levels of CoQ10 is not clear, and data on intramuscular CoQ10 leve

119 The interaction between sapB and CoQ10 is poorly understood.

120 Current literature suggests that CoQ10 is relatively safe with few drug interactions and

121 Thus, Coq10 is required for the function of Q(6) in respiratio

122 ired (coq10-L96S) or truncated (coq10-R147*) Coq10 isoform using CRISPR-Cas9.

123 strains expressing a functionally impaired (coq10-L96S) or truncated (coq10-R147*) Coq10 isoform usi

124 o examined the association between leukocyte CoQ10 levels and muscle markers, muscle performance, and

125 Mutations in ADCK4 resulted in reduced CoQ10 levels and reduced mitochondrial respiratory enzym

126 CoQ10 levels did not differ among symptomatic (2.3 nmol/

127 oQ10 is not clear, and data on intramuscular CoQ10 levels in symptomatic patients with statin-associa

128 CoQ10 levels in the retina can decline by approximately

129 guage articles relating statin treatment and CoQ10 levels via a PubMed search through August 2006.

130 he relationship between statin treatment and CoQ10 levels were examined in detail.

131 injury markers were not related to leukocyte CoQ10 levels.

132 uscle injury caused by reduced coenzyme Q10 (CoQ10) levels, which are postulated to produce mitochond

133 minergic axons in aged mice and suggest that CoQ10 may be useful in the treatment of Parkinson's dise

134 long-term administration of the antioxidant CoQ10 may represent a promising therapeutic strategy for

135 Coenzyme Q10 (CoQ10) may represent a safe therapeutic option for patie

136 Suggestions that CoQ10 might reduce the toxicity of cancer treatments hav

137 We show that both coq10 mutants preserve Mdm12 protein content and exhibit

138 The effect of CoQ10 on the physico-chemical stability of emulsions was

139 port the important role of the coenzyme Q10 (CoQ10) on the activity of caspase-2 upstream of mitochon

140 randomly assigned to either hypothermia plus CoQ10 or hypothermia plus placebo after CPR.

141 ly assigned to receive placebo, 1200 mg/d of CoQ10, or 2400 mg/d of CoQ10; all participants received

142 ve to placebo), and 8.0 points (2400 mg/d of CoQ10; P = .21 relative to placebo).

143 9 points (placebo), 7.5 points (1200 mg/d of CoQ10; P = .49 relative to placebo), and 8.0 points (240

144 Nine CoQ10 patients versus 5 placebo patients survived with a

145 that controls ROS formation independently of CoQ10, phenocopied the effect of Coq2-RNAi.

146 digestion and HPLC analysis to quantify the CoQ10 present in fortified products (100mg/g).

147 The pretreatment of CoQ10 prevented EtOH-induced caspase-2 activation and mi

148 This corresponds with the deficit in CoQ10 previously described in MSA and reflects the high

149 While Coq10 protein content is maintained upon deletion of MDM

150 Incorporation of CoQ10 provided protection from adriamycin-induced mitoch

151 The results suggested that CoQ10 provides some protection against cardiotoxicity or

152 efficient CoQ biosynthesis observed for the coq10-R147* mutant suggests these deleterious phenotypes

153 tionally impaired (coq10-L96S) or truncated (coq10-R147*) Coq10 isoform using CRISPR-Cas9.

154 berberine groups (P<0.05) and the levels of CoQ10 remained within normal values in supplemented subj

155 and levels of coenzymes Q9 and Q10 (CoQ9 and CoQ10, respectively) as indicators of endogenous antioxi

156 ging (MRI) markers, disease progression, and CoQ10 response data.

157 ntaining homologs of CoQ, including CoQ9 and CoQ10, resulted in the essentially complete reduction of

158 Deletion of COQ10 results in respiratory deficiency, impaired CoQ bi

159 CoQ10 retention of the emulsion and freeze dried product

160 like the coq10Delta mutant, indicating that Coq10's function is vital for respiration regardless of

161 ng a common component of cellular membranes, CoQ10's most prominent role is to facilitate the product

162 -I and Co-II shifts O*2- generation from the CoQ10 sites to more proximal sites, such as flavines, an

163 erate improvement of the fraction of reduced CoQ10, suggesting limited efficacy of NAC monotherapy.

164 urther proving that the metabolic effects of CoQ10 supplementation are mediated by the overexpression

165 in major adverse cardiovascular events with CoQ10 supplementation in a contemporary HF population.

166 anisms, clinical data, and safety profile of CoQ10 supplementation in patients with HF.

167 his study has renewed interest in evaluating CoQ10 supplementation in patients with HF.

168 tely powered randomized controlled trials of CoQ10 supplementation in patients with HF.

169 ortant to evaluate the potential benefits of CoQ10 supplementation in the clinical outcome of the dis

170 CoQ10 supplementation increased (P < 0.01) hepatic CoQ10

171 lism and may explain some of the benefits of CoQ10 supplementation observed in mitochondrial diseases

172 g levels of CoQ10, but data on the effect of CoQ10 supplementation on myopathic symptoms are scarce a

173 CoQ10 supplementation prevented liver fibrosis accompani

174 CoQ10 supplementation was initiated following these gene

175 or secondary variants may benefit from oral CoQ10 supplementation.

176 causes of ARCAs as some patients respond to CoQ10 supplementation.

177 ard diet and one group that had received the CoQ10 supplemented diet were treated with MPTP.

178 ary CoQ10 deficiencies, a potential role for CoQ10 supplements in cardiovascular disease, particularl

179 Current evidence for a benefit of CoQ10 supplements in diseases other than primary CoQ10 d

180 While the therapeutic utility of CoQ10 supplements is recognized in the rare cases of pri

181 Restoration of CoQ10 synthesis by vanillic acid partially rescued the p

182 s were fortified with a micellarized form of CoQ10 to enhance solubility to a concentration of 1mg/g

183 for oral supplementation with coenzyme Q10 (CoQ10) to improve the tolerability of cancer treatments.

184 ipid peroxidation by recycling coenzyme Q10 (CoQ10) to its lipophilic antioxidant form.

185 0 could be a mechanism to avoid any possible CoQ10 toxicity.

186 ally completely absent after the 6-mo, daily CoQ10 treatment in db(-)/db(-) mice when started at 7 wk

187 CoQ10 treatment led to improvement by clinical report in

188 ift mutation had partial remission following CoQ10 treatment.

189 and this effect was also blocked by the 6-mo CoQ10 treatment.

190 10, which encodes the putative CoQ chaperone Coq10, via a shared bidirectional promoter.

191 CoQ10 was dissolved in rice bran oil and incorporated in

192 Leukocyte CoQ10 was measured at baseline.

193 The emulsion with CoQ10 was used as a functional cream in the cheese makin

194 Coenzyme Q10 (CoQ10) was encapsulated successfully in a nutraceutical

195 verse effects of alcohol while coenzyme Q10 (CoQ10) was not very effective against alcohol insults.

196 enotypes resulting solely due to the loss of Coq10, we constructed strains expressing a functionally

197 Respiratory-chain enzyme activities and CoQ10 were decreased in severely affected patients but r

198 Manufacturers of CoQ10 were identified and contacted.

199 e similar in both groups; no side effects of CoQ10 were identified.

200 tosolic subunit of ERMES is coexpressed with COQ10, which encodes the putative CoQ chaperone Coq10, v

201 Combining CoQ10 with mild hypothermia immediately after CPR appear

202 d of CoQ10, and 17 who received 2400 mg/d of CoQ10) withdrew prematurely.

203 mentation with the antioxidant coenzyme Q10 (CoQ10) would prevent this programmed phenotype.